title: Relative level of thymidylate synthase mRNA expression in primary tumors and normal tissues predicts survival of patients with oral tongue squamous cell carcinoma.
abstract: Thymidylate synthase (TS) is a major target of 5-fluorouracil (5-FU) and dihydropyrimidine dehydrogenase (DPD) is a rate-limiting enzyme in the degradation of 5-FU. There are no studies investigating the comparison of TS and DPD mRNA expressions in oral tongue SCC (OSCC) and nontumor tissues obtained from the same patients. In addition, increased interest has been focused on the biological roles of TS and DPD as the independent prognostic factors as well as responsive determinants for cancer patients with 5-FU based therapy. We determined the expression levels of TS and DPD in tumor (T) and nontumor squamous epithelial tissues (N) of OSCC using real-time reverse transcription-polymerase chain reaction and evaluated whether the T/N ratio would correlate with clinicopathological factors. The mRNA expressions of TS and DPD were significantly higher in tumor areas than in nontumor areas. No correlation was found between the T/N ratio of each mRNA expression and gender, clinical stage, T classification, N classification or differentiation. The T/N ratio of TS in patients that died of disease was significantly higher than in patients with free of disease, whereas there were no relationships between The T/N ratio of DPD and disease status. Clinical follow-up data showed shorter overall survival periods for cases with high T/N ratio of TS than for cases with low T/N ratio of TS with the statistically significant. Our study showed that TS but not DPD seems to have prognostic value in OSCC. These findings suggest that the assessment of TS activity may be useful both in the management and in the treatment of OSCC.
authors.affiliation: Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. yasuryuj@qent.med.kyushu-u.ac.jp
authors.forename: Ryuji
authors.initials: R
authors.lastname: Yasumatsu
authors.forename: Torahiko
authors.initials: T
authors.lastname: Nakashima
authors.forename: Takahiro
authors.initials: T
authors.lastname: Wakasaki
authors.forename: Toranoshin
authors.initials: T
authors.lastname: Ayada
authors.forename: Hideki
authors.initials: H
authors.lastname: Kadota
authors.forename: Muneyuki
authors.initials: M
authors.lastname: Masuda
authors.forename: Satoshi
authors.initials: S
authors.lastname: Toh
authors.forename: Hideki
authors.initials: H
authors.lastname: Shiratsuchi
authors.forename: Shizuo
authors.initials: S
authors.lastname: Komune
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000201:enzymology* / Q000235:genetics* / Q000401:mortality; D017931:DNA Primers / Q000235:genetics; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000235:genetics*; D015996:Survival Rate; D013940:Thymidylate Synthase / Q000378:metabolism*; D014062:Tongue Neoplasms / Q000201:enzymology* / Q000235:genetics* / Q000401:mortality; D055815:Young Adult
chemical_list: D017931:DNA Primers; D012333:RNA, Messenger; D013940:Thymidylate Synthase
references.citation: Cancer Sci. 2003 Jul;94(7):633-8
references.pmid: 12841874
references.citation: Biochem Biophys Res Commun. 1972 Sep 26;48(6):1565-71
references.pmid: 4263280
references.citation: Histol Histopathol. 2004 Jan;19(1):129-36
references.pmid: 14702180
references.citation: Int J Cancer. 2004 Dec 20;112(6):967-73
references.pmid: 15316940
references.citation: Br J Cancer. 2005 Apr 11;92(7):1231-9
references.pmid: 15785747
references.citation: BMC Cancer. 2008 Jul 25;8:210
references.pmid: 18652704
references.citation: Anticancer Res. 2004 Jul-Aug;24(4):2495-501
references.pmid: 15330204
references.citation: Oral Oncol. 2005 Jan;41(1):38-47
references.pmid: 15598584
references.citation: Chemotherapy. 2007;53(1):36-41
references.pmid: 17192711
references.citation: Oncol Rep. 2006 Dec;16(6):1165-72
references.pmid: 17089033
references.citation: Virchows Arch. 2003 Nov;443(5):672-7
references.pmid: 12910418
references.citation: Anticancer Res. 2002 Mar-Apr;22(2A):761-8
references.pmid: 12014648
references.citation: Chemotherapy. 2009;55(1):36-41
references.pmid: 19023200
references.citation: Int J Clin Oncol. 2002 Dec;7(6):335-42
references.pmid: 12494248
references.citation: J Surg Oncol. 2003 Mar;82(3):174-9
references.pmid: 12619061
references.citation: Int J Mol Med. 2008 Dec;22(6):709-16
references.pmid: 19020767
references.citation: Br J Cancer. 2002 Jan 21;86(2):222-5
references.pmid: 11870510
references.citation: Int J Oral Maxillofac Surg. 2006 Mar;35(3):258-64
references.pmid: 16280240
references.citation: Cancer. 1998 May 1;82(9):1626-31
references.pmid: 9576280
references.citation: Oncol Rep. 2006 Oct;16(4):721-7
references.pmid: 16969485
references.citation: Cancer Res. 1982 Feb;42(2):450-6
references.pmid: 6173112
references.citation: Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Dec;94(6):717-23
references.pmid: 12464897
references.citation: Int J Oncol. 2000 Jul;17(1):47-54
references.pmid: 10853017
references.citation: Proc Natl Acad Sci U S A. 1972 Jul;69(7):1855-7
references.pmid: 4505665
references.citation: Am J Physiol Lung Cell Mol Physiol. 2006 Oct;291(4):L619-27
references.pmid: 16617093